JP2011500035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500035A5 JP2011500035A5 JP2010529192A JP2010529192A JP2011500035A5 JP 2011500035 A5 JP2011500035 A5 JP 2011500035A5 JP 2010529192 A JP2010529192 A JP 2010529192A JP 2010529192 A JP2010529192 A JP 2010529192A JP 2011500035 A5 JP2011500035 A5 JP 2011500035A5
- Authority
- JP
- Japan
- Prior art keywords
- codon
- polynucleotide
- immune response
- synonymous
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 70
- 102000040430 polynucleotide Human genes 0.000 claims description 70
- 239000002157 polynucleotide Substances 0.000 claims description 70
- 108020004705 Codon Proteins 0.000 claims description 66
- 230000028993 immune response Effects 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 230000000368 destabilizing effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000193155 Clostridium botulinum Species 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010081690 Pertussis Toxin Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98014507P | 2007-10-15 | 2007-10-15 | |
| US60/980,145 | 2007-10-15 | ||
| PCT/AU2008/001463 WO2009049350A1 (en) | 2007-10-15 | 2008-10-02 | Expression system for modulating an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097256A Division JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500035A JP2011500035A (ja) | 2011-01-06 |
| JP2011500035A5 true JP2011500035A5 (enExample) | 2012-02-02 |
| JP5543921B2 JP5543921B2 (ja) | 2014-07-09 |
Family
ID=40566909
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529193A Pending JP2011500036A (ja) | 2007-10-15 | 2008-10-02 | 構築物系およびその使用 |
| JP2010529192A Active JP5543921B2 (ja) | 2007-10-15 | 2008-10-02 | 免疫応答をモジュレートするための発現系 |
| JP2014097256A Active JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
| JP2014147453A Pending JP2014221068A (ja) | 2007-10-15 | 2014-07-18 | 構築物系およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529193A Pending JP2011500036A (ja) | 2007-10-15 | 2008-10-02 | 構築物系およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097256A Active JP6155223B2 (ja) | 2007-10-15 | 2014-05-09 | 免疫応答をモジュレートするための発現系 |
| JP2014147453A Pending JP2014221068A (ja) | 2007-10-15 | 2014-07-18 | 構築物系およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9593340B2 (enExample) |
| EP (2) | EP2215269B1 (enExample) |
| JP (4) | JP2011500036A (enExample) |
| AU (2) | AU2008314485B9 (enExample) |
| DK (1) | DK2215269T3 (enExample) |
| ES (1) | ES2662030T3 (enExample) |
| WO (2) | WO2009049350A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2139515T5 (pl) | 2007-03-30 | 2024-04-08 | The Research Foundation Of The State University Of New York | Atenuowane wirusy przydatne w szczepionkach |
| WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| LT3444268T (lt) * | 2010-05-05 | 2022-04-11 | New York University | Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| US9918724B2 (en) | 2012-12-27 | 2018-03-20 | Wright Medical Technology, Inc. | Ankle replacement system and method |
| WO2014150841A2 (en) * | 2013-03-15 | 2014-09-25 | Dow Corning Corporation | Powdered resin linear organopolysiloxane compositions |
| EP3054971B1 (en) * | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| CN106999572A (zh) * | 2014-10-01 | 2017-08-01 | 阿德梅杜斯疫苗有限公司 | 用于诱导对单纯疱疹病毒2型(hsv‑2)的免疫应答的治疗组合物和方法 |
| WO2016086988A1 (en) * | 2014-12-03 | 2016-06-09 | Wageningen Universiteit | Optimisation of coding sequence for functional protein expression |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| US10724040B2 (en) | 2015-07-15 | 2020-07-28 | The Penn State Research Foundation | mRNA sequences to control co-translational folding of proteins |
| RU2744193C2 (ru) * | 2015-10-16 | 2021-03-03 | Канзас Стейт Юниверсити Рисерч Фаундейшн | Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения |
| CN108601951B (zh) * | 2015-12-09 | 2022-11-22 | 金港医疗(澳大利亚)私人有限公司 | 用于治疗的免疫调节组合物 |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) * | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| CN114222579A (zh) * | 2019-04-04 | 2022-03-22 | 勃林格殷格翰动物保健美国有限公司 | 猪圆环病毒3型（pcv3）疫苗及其生产和用途 |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| CN113461798A (zh) * | 2020-03-18 | 2021-10-01 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN115704012A (zh) * | 2021-08-12 | 2023-02-17 | 中国科学院深圳先进技术研究院 | 一种含有降解决定子的重组病毒及其制备方法和应用 |
| CN117448254B (zh) * | 2023-10-23 | 2024-04-09 | 广州梵之容化妆品有限公司 | 一种光果甘草干细胞的制备方法及用途 |
| CN120060262B (zh) * | 2025-04-25 | 2025-08-12 | 中国农业科学院茶叶研究所 | 茶树CsU3启动子及其应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4184917A (en) | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| US4321365A (en) | 1977-10-19 | 1982-03-23 | Research Corporation | Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules |
| US4293652A (en) | 1979-05-25 | 1981-10-06 | Cetus Corporation | Method for synthesizing DNA sequentially |
| US4351901A (en) | 1980-03-24 | 1982-09-28 | Cetus Corporation | Method for single nucleotide alteration |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US5093242A (en) | 1986-10-02 | 1992-03-03 | Massachusetts Institute Of Technology | Methods of generating desired amino-terminal residues in proteins |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| DE10399032I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5179022A (en) | 1988-02-29 | 1993-01-12 | E. I. Du Pont De Nemours & Co. | Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner |
| CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| DE3909710A1 (de) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur expression eines rekombinanten gens |
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
| FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| US5122463A (en) | 1990-05-17 | 1992-06-16 | Massachusetts Institute Of Technology | Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| EP0549723A1 (en) | 1990-09-21 | 1993-07-07 | Chiron Corporation | Packaging cells |
| ATE188740T1 (de) | 1991-02-19 | 2000-01-15 | Univ California | Viruspartikel mit veraendertem wirtspektrum |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| AU3972893A (en) | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
| AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| AU680508B2 (en) | 1993-04-06 | 1997-07-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Gibbon ape leukemia virus-based retroviral vectors |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US6120764A (en) | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
| US6140087A (en) | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JPH07105638A (ja) * | 1993-10-05 | 1995-04-21 | Matsushita Electric Ind Co Ltd | 画像データの記録再生装置 |
| AU7353494A (en) | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
| WO1995019799A1 (en) | 1994-01-21 | 1995-07-27 | Agracetus, Inc. | Gas driven gene delivery instrument |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5833993A (en) | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| GB9506782D0 (en) | 1995-04-01 | 1995-05-24 | British Biotech Pharm | Retroviral vectors |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2247091A1 (en) | 1996-03-05 | 1997-09-12 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6818222B1 (en) * | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
| CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| AUPP807899A0 (en) * | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
| WO2000000600A2 (en) | 1997-09-22 | 2000-01-06 | Chang Lung Ji | Lentiviral vectors, comprising modified major donor splice sites and major packaging signals |
| ATE298371T1 (de) | 1997-09-24 | 2005-07-15 | Univ California | Nicht-primaten lentivirale vektoren und verpackungssysteme |
| WO1999024465A1 (en) | 1997-11-10 | 1999-05-20 | Dana-Farber Cancer Institute | Stabilized primate lentivirus envelope glycoproteins |
| JP2002508338A (ja) | 1997-12-12 | 2002-03-19 | ナルディニ，ルイジ | レンチウィルスベクターの治療使用 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
| AUPP807799A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Polynucleotide and method |
| CA2373300C (en) | 1999-04-14 | 2012-02-21 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| WO2001081609A2 (en) | 2000-03-22 | 2001-11-01 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| WO2004024915A1 (en) | 2002-09-13 | 2004-03-25 | The University Of Queensland | Gene expression system based on codon translation efficiency |
| AU2003275776B2 (en) * | 2002-11-08 | 2009-06-18 | Jingang Medicine (Australia) Pty Ltd | A method for optimising gene expression using synonymous codon optimisation |
| US7628993B2 (en) * | 2006-07-20 | 2009-12-08 | Vical Incorporated | Compositions and methods for vaccinating against HSV-2 |
| WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
-
2008
- 2008-10-02 WO PCT/AU2008/001463 patent/WO2009049350A1/en not_active Ceased
- 2008-10-02 EP EP08800100.3A patent/EP2215269B1/en active Active
- 2008-10-02 US US12/738,284 patent/US9593340B2/en active Active
- 2008-10-02 EP EP08800098A patent/EP2215231A4/en not_active Withdrawn
- 2008-10-02 JP JP2010529193A patent/JP2011500036A/ja active Pending
- 2008-10-02 WO PCT/AU2008/001465 patent/WO2009049351A1/en not_active Ceased
- 2008-10-02 ES ES08800100.3T patent/ES2662030T3/es active Active
- 2008-10-02 US US12/738,291 patent/US20120040367A1/en not_active Abandoned
- 2008-10-02 AU AU2008314485A patent/AU2008314485B9/en not_active Ceased
- 2008-10-02 AU AU2008314486A patent/AU2008314486B2/en not_active Ceased
- 2008-10-02 JP JP2010529192A patent/JP5543921B2/ja active Active
- 2008-10-02 DK DK08800100.3T patent/DK2215269T3/en active
-
2014
- 2014-05-09 JP JP2014097256A patent/JP6155223B2/ja active Active
- 2014-07-18 JP JP2014147453A patent/JP2014221068A/ja active Pending
-
2017
- 2017-01-17 US US15/408,201 patent/US20170218393A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11998597B2 (en) | Vaccine against RSV | |
| CN107434827B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| US20210275664A1 (en) | Prefusion coronavirus spike proteins and their use | |
| CN105408348B (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| JP2013529077A5 (enExample) | ||
| JP6505110B2 (ja) | ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用 | |
| JP2011528222A5 (enExample) | ||
| CN105188745A (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| EP3319634A1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
| CN106061995A (zh) | Uspa2蛋白质构建体及其用途 | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| EP3279217A1 (en) | Streptococcus pneumoniae protein antigen, and preparation method and use thereof | |
| AU2021269320A1 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
| AU2025205220A1 (en) | Vaccine polypeptide compositions and methods | |
| CN100582122C (zh) | O型口蹄疫病毒多表位粘膜免疫疫苗及其应用 | |
| CN118725052A (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| TW202038997A (zh) | 胜肽之血中動態改善方法 | |
| CN107034198A (zh) | 一种嵌合诺如病毒p颗粒及其制备和应用 | |
| RU2005101744A (ru) | Последовательность днк и получение аллергена пыльцы трав ph1 p4 с помощью рекомбинантных способов | |
| CN121021709B (zh) | 一种猪链球菌2型多表位吸入式亚单位疫苗及其应用 | |
| Quintana-Vázquez et al. | Recombinant hybrid proteins from pertactin type 1 and 2 of Bordetella pertussis are more immunogenic in mice than the original molecules | |
| CN102516373B (zh) | 去除人同源性的肺炎链球菌表面蛋白a、纯化方法及用途 | |
| EP1294890A2 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis | |
| RU2794625C2 (ru) | Пневмококковая вакцина, сочетающая выбранные альфа-спиральные домены и богатые пролином домены пневмококкового поверхностного белка а | |
| CA3044112C (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a |